Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 9/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231474 | 0.94 | MRGPRX4 (0.63) | MRGPRX4NR4A2MAOBPOLBMAPT | |
| SCHEMBL5669711 | 0.90 | MAOB (0.74) | MRGPRX4NR4A2MAOBPOLBMAPT | |
| SCHEMBL10335673 | 0.90 | MAOB (0.65) | MRGPRX4NR4A2MAOB | |
| SCHEMBL5990835 | 0.87 | MRGPRX4 (0.56) | MRGPRX4NR4A2MAOBPPARGPPARA | |
| SCHEMBL16804808 | 0.85 | MAOB (0.62) | MRGPRX4NR4A2MAOBMAPT | |
| SCHEMBL18164441 | 0.85 | MAOB (0.57) | MRGPRX4NR4A2MAOBPOLBMAPT | |
| SCHEMBL11790839 | 0.85 | MRGPRX4 (0.57) | MRGPRX4NR4A2MAOBPPARG | |
| SCHEMBL18164545 | 0.84 | MAOB (0.63) | MRGPRX4NR4A2MAOBPOLBMAPT | |
| SCHEMBL18164564 | 0.84 | MAOB (0.59) | MRGPRX4NR4A2MAOBMAPT | |
| SCHEMBL18161388 | 0.84 | NR4A2 (0.60) | MRGPRX4NR4A2MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1194952-C | Green synthetic process for high efficiency low poison pesticide and medicinal intermediate trifluoromethylphenol | SHANGDONG NORMAL UNIV (CN) | 2005-03-30 | — | — | CN | claimed |
| CN-1425638-A | Green synthetic process for high efficiency low poison pesticide and medicinal intermediate trifluoromethylphenol | UNIV SHANDONG (CN) | 2003-06-25 | — | — | CN | claimed |
| EP-0028305-B1 | DIARYL COMPOUNDS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-02-01 | — | — | EP | claimed |
| EP-1551814-B1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7348349-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20050267180-A1 | Novel oxazole derivatives | BINGGELI ALFRED | 2005-12-01 | — | — | US | disclosed |
| US-6969725-B2 | Oxazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1551814-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| CN-1194952-C | Green synthetic process for high efficiency low poison pesticide and medicinal intermediate trifluoromethylphenol | SHANGDONG NORMAL UNIV (CN) | 2005-03-30 | — | — | CN | disclosed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| CN-1425638-A | Green synthetic process for high efficiency low poison pesticide and medicinal intermediate trifluoromethylphenol | UNIV SHANDONG (CN) | 2003-06-25 | — | — | CN | disclosed |
| EP-0028305-B1 | DIARYL COMPOUNDS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-02-01 | — | — | EP | disclosed |
| EP-0004447-B1 | PREPARATION OF TRIFLUOROMETHYLPHENOLS AND NOVEL TRIFLUOROMETHYLPHENYL BENZYL ETHER INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1981-12-02 | — | — | EP | disclosed |
| EP-0004447-A2 | Preparation of trifluoromethylphenols and novel trifluoromethylphenyl benzyl ether intermediates | ELI LILLY AND COMPANY (US) | 1979-10-03 | — | — | EP | disclosed |
| US-4168388-A | Trifluoromethylphenyl benzyl ethers | ELI LILLY AND COMPANY (US) | 1979-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267180-A1 | Novel oxazole derivatives | NR1H3, NR1H2, PPARD | MRGPRX4 2174/4885NR4A2 126/4885MAOB 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.